Naseem Amin, Orphalan CEO (via Orphalan website)
Wilson's disease treatment from Orphalan gets the go-ahead after PhIII
Cuvrior, the Orphalan treatment for adult patients with stable Wilson’s disease, has gotten approval from the FDA.
The OK comes after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
